Andy Kistler, MD, PharmD

Biliary reflux is difficult, yet important, to distinguish from acid reflux, in order to ensure proper treatment for these patients.

Researchers conducted a meta-analysis to evaluate prophylactic clipping in preventing post-polypectomy bleeding and published the results in Gastroenterology.

There is significant interest in optimizing medical treatments of Crohn’s disease (CD) in hopes of preventing complications and the need for surgery.

There are increasing data to support that many patients with COVID-19 can develop a myriad of gastrointestinal symptoms, which include mild diarrhea, nausea, vomiting and abdominal pain.

It is thought that dysregulation of the gut microbiome could cause increased production of pro-inflammatory toxins that can predispose patients to the development of UC.

An area that has been specifically challenging within gastroenterology is the management of how and when to perform GI procedures, especially when many patients with COVID-19 have gastrointestinal (GI) symptoms.

Surveillance recommendations are based on the initial grade of dysplasia.

Researchers evaluated the efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders, in patients with moderate to severe ulcerative colitis.

The absolute 1-year risk of colorectal cancer in patients with atrial fibrillation treated with oral anticoagulants is not trivial.

Although patients with COVID-19 are known to present with constitutional and respiratory symptoms such as fever, cough, sore throat, and shortness of breath, there is growing evidence that these patients can also experience significant gastrointestinal symptoms such as nausea, vomiting, and diarrhea.